DALLAS--(BUSINESS WIRE)--Peloton Therapeutics, Inc., announced today the appointment of two new members to the company’s Board of Directors. The new members are Helen S. Kim, former Executive Vice President of Business Development at Kite Pharma, Inc., a Gilead Company, and David D. Chang, M.D., Ph.D., who currently serves as Executive Vice President, Research & Development, and Chief Medical Officer of Kite. Both have joined as independent directors.
“We are quite pleased each of these individuals are joining the Board of Directors at Peloton Therapeutics as they bring significant scientific, clinical development, strategic and corporate development expertise to the organization,” said John A. Josey, Ph.D., Peloton’s Chief Executive Officer. “Ms. Kim’s business development leadership in biotechnology and Dr. Chang’s deep knowledge of oncology drug development and immuno-oncology will help inform our strategy as we continue to advance our innovative pipeline programs in cancer.”
Ms. Kim most recently served as Executive Vice President of Business Development at Kite Pharma, Inc., where she led the acquisition of Kite Pharma by Gilead in 2017. Previously, Ms. Kim served as Strategic Advisor and Chief Business Officer at NGM Biopharmaceuticals, Inc. She also served as the Chief Executive Officer and President of Kosan Biosciences Inc., during which time she restructured and repositioned the company prior to successfully negotiating its sale to Bristol-Myers Squibb in 2008. Ms. Kim has held executive positions at Affymax, Onyx Pharmaceuticals, Protein Design Labs and Chiron Corporation. In addition to her industry experience, Ms. Kim recently served as Chief Program Officer for the Gordon and Betty Moore Foundation. Currently, she serves as a Director of the Board of Exicure Therapeutics. Ms. Kim received a B.S. in Chemical Engineering from Northwestern University and a M.B.A. from the University of Chicago.
Dr. Chang has an industry-leading track record of innovation in the field of oncology drug development, including the development for Yescarta™ (axicabtagene ciloleucel), the first CAR T therapy approved for non-Hodgkin lymphoma. Dr. Chang also held senior leadership roles at Amgen, including Vice President of Global Development and Head of Hematology-Oncology. Prior to joining Amgen, Dr. Chang held dual appointments as Associate Professor of Medicine, and of Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at the University of California, Los Angeles. He is also a venture partner at Vida Ventures and a member of the scientific advisory board to Kronos Bio. Dr. Chang obtained a B.S. degree in Biology from the Massachusetts Institute of Technology and M.D. and Ph.D. degrees from Stanford University. He completed an internship and residency in internal medicine at Brigham and Women’s Hospital and a fellowship in medical oncology at Dana-Farber Cancer Institute at Harvard Medical School, where he was a Howard Hughes Medical Institute postdoctoral fellow.
About Peloton Therapeutics
Peloton Therapeutics, Inc. is a clinical-stage pharmaceutical company that is translating groundbreaking scientific insights into first-in-class oral medicines for patients with cancer and other serious or life-threatening conditions. The Company’s lead development program is evaluating the only clinical stage small-molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of kidney cancer and a wide variety of other disorders. Peloton is also progressing several research programs by building upon its success in inhibiting HIF-2α, which was previously thought to be intractable using small molecules.
To learn more about Peloton Therapeutics, visit www.pelotontherapeutics.com.
© 2018 Peloton Therapeutics, Inc.
All Rights Reserved